The history of Viagra and its originator, copyright, presents a complex picture for prospective investors. While the revolutionary drug initially generated enormous earnings, its patent has ended, leading to rival versions flooding the arena. This decline in cost presents a significant challenge for copyright and any company considering a heavy hol